Cardiac oncology is an emerging area of ??interest in cardiology focused on the detection, monitoring, and treatment of cardiovascular disease that occurs as a side effect of chemotherapy and radiation therapy. Both cancer therapies can cause cardiac dysfunction, which is a major cause of morbidity and mortality in the oncology population. For cancer patients undergoing treatment, especially those receiving anthracyclines and trastuzumab (monoclonal antibody), 3D echocardiography is primarily used to calculate left ventricular ejection fraction and estimate myocardial deformation. For example, regular monitoring is required. Additionally, measurement of various biomarkers such as natriuretic peptides may facilitate early identification and appropriate response to potential cardiotoxicity. In this context, cardiac evaluation is essential before initiating cancer therapy and should be continued throughout treatment, as cardiac dysfunction can occur at any time, even years after initiation of therapy. there is. In particular, high-risk individuals should receive detailed treatment plans developed in collaboration with oncology and cardiology specialists.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
